<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28279">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01724216</url>
  </required_header>
  <id_info>
    <org_study_id>114-2012-GES-0014</org_study_id>
    <nct_id>NCT01724216</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging Using Innovative Pulse Sequences</brief_title>
  <official_title>Magnetic Resonance Imaging Using Innovative Pulse Sequences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to collect in vivo human image data to demonstrate neurological
      magnetic resonance imaging of subjects using short pulse sequences.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Head Images</measure>
    <time_frame>6-months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Collect head human images and associated technical and clinical information to demonstrate neurological magnetic resonance imaging of subjects using short pulse sequence.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Head Images With and Without Contrast</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging Using Innovative Pulse Sequences</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be at least 18 years of age

          -  Subject must be willing and able to undergo verbal and written informed consent

          -  Subject must have a clinical indication for a head MRI with and without
             Gadolinium-based contrast agent administration

        Exclusion Criteria:

          -  Subjects who have any of the conditions below at the time of the enrollment or scan
             session are excluded from this study. Further, should it be determined by study staff
             that an enrolled subject meets any of the conditions below during the course of the
             study, the subject will be removed from the study.

               -  Any contraindication to an MRI scan per the policy of Spectrum Health

               -  Any contraindication to administration of an MRI contrast agent per the policy
                  of Spectrum Health

               -  Off-label utilization of contrast agents administered for the subject's clinical
                  exam
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark C DeLano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spectrum Health Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Dekoff, CRN</last_name>
    <phone>616-391-9365</phone>
    <email>nancy.dekoff@spectrumhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim McClain, CRN</last_name>
    <phone>616-391-2883</phone>
    <email>kimberly.mcclain@spectrumhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Dekoff, CRN</last_name>
      <phone>616-391-9365</phone>
      <email>nancy.dekoff@spectrumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Kim McClain, CRN</last_name>
      <phone>616-391-2883</phone>
      <email>kimberly.mcclain@spectrumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mark C DeLano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>November 8, 2012</lastchanged_date>
  <firstreceived_date>November 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
